Prognostic Implication of CYP2C19 Genotype According to Clinical Risk Stratification After Drug-Eluting Stent...

Area of Science:

• Pharmacogenomics
• Cardiovascular Medicine
• Interventional Cardiology

Background:

• Clopidogrel efficacy is influenced by CYP2C19 genotype.
• The prognostic impact of CYP2C19 genotype in drug-eluting stent (DES) patients with varying clinical risk remains unclear.

Purpose of the Study:

• To evaluate the prognostic significance of CYP2C19 genotypes in DES-treated patients stratified by clinical risk.
• To assess the association between CYP2C19 loss-of-function (LoF) alleles and clinical outcomes.

Main Methods:

• Retrospective analysis of 8,163 clopidogrel-treated patients from the PTRG-DES consortium.
• Classification of patients based on CYP2C19 metabolizer status (RMs/NMs vs. IMs/PMs) and clinical risk scores (CHADS-P2A2RC, TRS 2°P).
• Primary endpoint: composite of cardiac death, myocardial infarction, and stent thrombosis over 3 years.

Main Results:

• Intermediate or poor CYP2C19 metabolizers (IMs/PMs) had a significantly higher risk of the primary endpoint compared to rapid or normal metabolizers (RMs/NMs) (HR: 1.48).
• This increased risk was most pronounced in patients with high CHADS-P2A2RC (adjusted HR [aHR]: 1.68) and TRS 2°P (aHR: 1.63) scores.
• An interaction between acute coronary syndrome and genotype was observed for both risk scores, indicating differential impact based on presentation.

Conclusions:

• CYP2C19 LoF allele carriage is associated with increased ischemic risk in clopidogrel-treated DES patients.
• Risk stratification by clinical scores and CYP2C19 genotype is crucial, particularly for high-risk individuals and those presenting with acute coronary syndrome.
• Genotype-guided antiplatelet therapy may optimize outcomes in this patient population.